TFC 612

prevents decrease in motor nerve conduction velocity in streptozocin-diabetic rats; derivative of thiaprostaglandin E1; has antinephritic effects

Also Known As:

TEI 6122; TEI-6122; TFC-612; methyl 6-((-3-hydroxy-2-(3-hydroxy-5-methyl-1-nonenyl)-5-oxocyclopentyl)thio)hexanoate

Networked: 6 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - Unsaturated Fatty Acids: 8236
    - Eicosanoids: 3262
      - Prostaglandins: 17100
        Prostaglandins E: 2673
        Alprostadil: 3107
        TFC 612: 6
    - Monounsaturated Fatty Acids: 676
      - Alprostadil: 3107
        TFC 612: 6
Biological Factors: 2472
- Inflammation Mediators: 1113
  - Autacoids: 276
    - Eicosanoids: 3262
      - Prostaglandins: 17100
        Prostaglandins E: 2673
        Alprostadil: 3107
        TFC 612: 6

Related Diseases

1.	Ischemia 07/01/1989 - "With the laser Doppler flowmetry technique, a decrease in the sciatic nerve blood flow in diabetic rats was shown to improve with both compounds, but TFC 612 had a greater effect than ONO 2235, and the increased lactate level of the diabetic nerve was corrected with both compounds, suggesting that both may be associated with the amelioration of ischemia in the diabetic endoneurium. "
2.	Body Weight (Weight, Body) 11/01/1990 - "In addition, 1 month administration of TFC-612 significantly improved the reduced MCV in aged (5 month-old) GK rats only in the high dose group (0.3 mg/kg body weight), but not in the low dose group (0.03 mg/kg body weight). "
3.	Diabetic Neuropathies (Diabetic Neuropathy) 07/01/1989 - "These results suggest that the PGE1 analogue TFC 612 has a significant effect on diabetic neuropathy, possibly via vasotropic action, and may be a potent compound for the treatment of diabetic neuropathy." 07/01/1989 - "Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. " 01/15/1988 - "The results suggest that TFC-612 has a potent effect on diabetic nerve dysfunction via other mechanism than the correction of sorbitol and myo-inositol metabolisms and could be a potential compound for therapy of diabetic polyneuropathy." 07/01/1989 - "The effect of a newly developed oral agent, prostaglandin E1 (PGE1) analogue TFC 612, on diabetic neuropathy was studied by giving it for 6 wk to streptozocin-induced diabetic rats that had been diabetic for 3 mo and was compared with the effects of aldose reductase inhibitor ONO 2235. "
4.	Thrombosis (Thrombus) 01/01/1992 - "These results suggest that the enhancement of fibrinolytic activity by TFC-612, which may be due to an increase in tissue plasminogen activator release or reduction of plasminogen activator inhibitors release, contributes to its inhibition of thrombus formation." 01/01/1992 - "TFC-612 inhibited thrombus formation on wire coils inserted into the lumen of the inferior vena cava of rats after 5 oral doses of 1.0 and 3.2 mg/kg and subcutaneous doses of 1.0 and 3.2 micrograms/rat/hr. This compound showed slight inhibition of platelet aggregation induced by collagen at 1.0 and 3.2 mg/kg (po) and significant inhibition at 10 mg/kg. TFC-612 had no effect on the plasma coagulation system at 3.2 mg/kg. Conversely, oral doses of 0.32-3.2 mg/kg dose- dependently enhanced fibrinolytic activity as measured by euglobulin clot lysis time and lysis area on fibrin plates by euglobulin fraction. "
5.	Nephritis 12/01/1989 - "The antinephritic effects of PGE1, TEI-5178 and TEI-6122 on crescentic-type anti-glomerular basement membrane (GBM) nephritis in rats were investigated. " 12/01/1989 - "PGE1 (2.0 mg/kg/day), TEI-5178 (0.25 or 0.5 mg/kg/day) and TEI-6122 (0.25 or 0.5 mg/kg/day) significantly reduced urinary protein by 30 to 50% of that of the control at the late stage of nephritis. " 12/01/1989 - "Antinephritic effects of PGE1 and thiaprostaglandin E1, TEI-5178 and TEI-6122, on crescentic-type anti-GBM nephritis in rats."

Related Drugs and Biologics

1.	Lactic Acid (Lactate)
2.	epalrestat
3.	Alprostadil (Muse)
4.	Plasminogen Inactivators
5.	Streptozocin (Streptozotocin)
6.	Sorbitol (Yal)
7.	Serum Globulins
8.	Proteins (Proteins, Gene)
9.	Tissue Plasminogen Activator (Alteplase)
10.	Inositol (Myoinositol)

Related Therapies and Procedures

1.	Lasers (Laser)
2.	Therapeutics